4-(c2-6alkoxy)-substituted chalcones as therapeutic agents

Details 4-(c2-6alkoxy)-substituted chalcones as therapeutic agents 4-(c2-6alkoxy)-substituted chalcones as therapeutic agents

2006-09-26

2006-09-26

Witherspoon, Sikarl A. (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Oxygen containing

C568S337000, C568S338000, C514S685000, C514S689000

Reexamination Certificate

active

07112698

ABSTRACT:
The present invention pertains to compounds of the following formula: (1) wherein: RALKis primary or secondary aliphatic saturated C2-6alkyl; each of RB2, RB3, RB4, and RB5is independently —H, —OH, or —OMe; each of R1and R2is independently: —H, optionally substituted C1-4alkyl, or optionally substituted C5-20aryl; RA3is —H, —OH, —OC(═O)RE, —OS(═O)2OH, or —OP(═O)(OH)2; REis: —H, optionally substituted C1-6alkyl, optionally substituted C3-20heterocyclyl, or optionally substituted C5-20aryl; or a pharmaceutically acceptable salt, solvate, amide, ester, ether, chemically protected form, or prodrug thereof. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, for both diagnosis and treatment of, for example, proliferative conditions, such as cancer, and inflammatory conditions

REFERENCES:
patent: 4279930 (1981-07-01), Hall et al.
patent: 4867964 (1989-09-01), Forestier et al.
patent: 5430062 (1995-07-01), Cushman et al.
patent: 5691373 (1997-11-01), Berryman et al.
patent: 6214886 (2001-04-01), Potter et al.
patent: 6787672 (2004-09-01), Potter et al.
patent: 2 198 945 (1988-06-01), None
patent: 61-076433 (1986-04-01), None
patent: 02-142717 (1990-05-01), None
patent: 05-246932 (1993-09-01), None
patent: 08-188546 (1996-07-01), None
patent: WO 95/05376 (1995-02-01), None
patent: WO 97/12246 (1997-04-01), None
patent: WO 99/00114 (1999-01-01), None
patent: WO 99/40056 (1999-08-01), None
patent: WO 01/46110 (2001-06-01), None
patent: WO 01/72680 (2001-10-01), None
Geismann et al. Flavonones and related compounds. V. The oxidation of 2′-hydroxychalcones with alkaline hydrogen peroxide. Journal of the American Chemical Society; (1948), vol. 70, p. 1686-1689.
Barrie, S.E., et al., 1989, “Inhibition of 17-hydroxylase/C17-C20 Lyase by Bifluranol and Its Analogues,”J. Steroid Biochem., vol. 33, No. 6, pp. 1191-1195.
Carmichael, J., et al., 1987, “Evaluation of a Tetrazolium-based Semiautomated Colorimetric Assay: Assessment of Chemosensitivity Testing,”Cancer Research, vol. 47, p. 936-942.
de Wet, H., et al., 2001, “Sequence Requirements of the ATP-Binding Site within the C-Terminal Nucleotide-Binding Domain of Mouse P-Glycoprotein: Structure-Activity Relationships for Flavonoid Binding,”Biochemistry, vol. 40, 10382-10391.
Ducki, S., et al., 1998, “Potent Antimitotic and Cell growth Inhibitory Properties of Substituted Chalcones,”BioMed. Chem. Lett., vol. 8, pp. 1051-1056.
Hsieh, H-K et al., 2000, “Synthesis and Anti-Inflammatory Effect of Chalcones,”Journal of Pharmacy and Pharmacology, vol. 52, No. 2, pp. 163-171.
Iwata Susumu et al., 1995, “Antitumorigenic Activities of Chalcones. I. Inhibitory Effects of Chalcone Derivatives on 32P-Incorporation into Phospholipids of HeLa Cells Promoted by 12-O-Tetradecanoyl-phorbol 13-acetate (TPA),”Biological&Pharmaceutical Bulletin(of Japan), vol. 18, No. 12, pp. 1710-1713.
Mosmann, T., 1983, “Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays,”Journal of Immunological Methods, vol. 65, pp. 55-63.
Murray, G. I., et al., 1997, “Tumour-specific Expression of Cytochrome P450 CYP1B1,”Cancer Research, vol. 57, pp. 3026-3031.
Parmar, V.S., et al., 1997, “Anti-Invasive Activity of Alkaloids and Polyphenolics in Vitro,”Bioorganic&Medicinal Chemistry, vol. 5, No. 8, pp. 1609-1619.
Pettit, G.R., et al., 1995, “Antineoplastic agents 322. Synthesis of Combretastatin A-4 Prodrugs,”Anticancer Drug Design, vol. 10, pp. 299-309.
Shibata, S., 1994, “Anti-Tumorigenic Chalcones,”Stem Cells, vol. 12, pp. 44-52.
Sogawa et al., 1993, “3,4-Dihydroxychalcones as Potent 5-Lipoxygenase and Cyclooxygenase Inhibitors,” Journal of Medicinal Chemistry, vol. 36, No. 24, pp. 3904-3909.
Spink, D.C., et al., 1994, “The Effects of 2,3,7,8-Tetrachlorodibenzo-p-dioxin on Estrogen Metabolism in MCF-7 Breast Cancer Cells: Evidence for Induction of a Novel 17β-Estradiol 4-hydroxylase,”J. Steroid Biochem. Mol. Biol., vol. 51, No. 5/6, pp. 251-258.
Sutter, T.R., et al, 1994, “Complete cDNA sequence of a human dioxin-inducible mRNA identifies a new gene subfamily of cytochrome P450 that maps onto chromosome 2,”J. Biol. Chem., vol. 269, No. 18, pp. 13092-13099.
Tanaka et al., 2001, “Influence of Natural and Synthesis Compounds on Cell Surface Expression of Cell Adhesion Molecules ICAM-1 and VCAM-1,”Planta Medica, vol. 67, No. 2, pp. 108-113.
Yamashita, D.S., et al, 1994, “Design, Synthesis and Evaluation of Dual Domain FKBP Ligands,”Bioorg. Med. Chem. Lett., vol. 4, No. 2, pp. 325-328.

Affiliated with

Also associated with

Rating

4-(c2-6alkoxy)-substituted chalcones as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 4-(c2-6alkoxy)-substituted chalcones as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-(c2-6alkoxy)-substituted chalcones as therapeutic agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3528661